Audit Company "Best-Audit" Since 1994

Member of Russian Chamber of Auditors (Association) AUDIT REPORT

Our Ref. No. 144 dated March 26, 2018

to Members of Sun Pharmaceutical Industries LLC Executive body of the Company

Opinion

We audited the attached accounting (financial) statements of the Limited Liability Company "Sun Pharmaceutical Industries" (OGRN 1077762356770, 129223, Moscow, prospect Mira Street, 119, building 537/6, suite 62), consisting of the Balance Sheet as of December 31, 2017, Profit and Loss Statement for 2017, annexes to the Balance Sheet and Profit and Loss Statement, namely: Statement of Changes in Equity for 2017 and Cash Flow Statement for 2017, explanations to the Balance Sheet and Profit and Profit and Loss Statement for 2017, explanations to the Balance Sheet and Profit and Loss Statement for 2017, including the brief review of main provisions of the accounting policy.

In our opinion, the attached annual accounting (financial) statements show reliably in all material aspects the financial status of the Limited Liability Company "Sun Pharmaceutical Industries" (hereinafter referred to as "the Company"), as of December 31, 2017, financial results of operation and cash flows during 2017 in compliance with the rules of accounting (financial) statements preparation, applicable in the Russian Federation.

Basis of opinion

We conducted the audit in compliance with International Audit Standards (IAS). Our responsibility in compliance with such standards is described in section "Responsibility of auditor for the audit of annual accounting (financial) statements" of this opinion. We are independent from the audited entity according to the Rules of independence of auditors and audit firms and Professional Code of Conduct of Auditors, corresponding to the Professional Code of Conduct of Chartered Accountants, developed by the Accounting Professional and Ethical Standards Board, and we did any other duties in compliance with such requirements of professional ethics. We believe that the audit evidences obtained by us are sufficient and reliable to serve as basis for our opinion.

Material uncertainty with respect to continuity of business

Please note Section 9 of Notes to the Balance Sheet and Profit and Loss Statement, stating that the figure of net assets of the Company as of December 31, 2017 is negative. The main reason is a loss incurred of the financial and business operations, arising mostly due to executive and any other expenses, and absence of commercial operations during 2017. We confirm that the information on such event was adequately stated in the attached accounting (financial) statements. We do not express a modified opinion in connection to such matter.

Responsibility of the management of audited entity for the annual accounting (financial) statements

The management of the Company is responsible for preparation and reliable presentation of the above annual accounting (financial) statements in compliance with Rules of preparation of accounting (financial) statements, applicable in the Russian Federation, and for the system of internal control, which the management deems necessary for preparation of annual accounting (financial) statements, without material misstatements due to improper actions or errors.

When preparing the annual accounting (financial) statements, the management of the Company bears the responsibility for assessment of ability of the audited entity to continue without interruptions its business, for disclosure in respective cases of data, referred to continuity of business, and for preparation of statements on the basis of assumption on continuity of business, except for the cases, when the management intends to wind up the audited entity, terminate its operations or when they do not have any real alternative, except for liquidation or termination of business.

Responsibility of auditor for audit of annual accounting (financial) statements

Our purpose is to obtain reasonable assurance about whether the annual accounting (financial) statements are free of material misstatements due to improper actions or errors, and preparation of audit report containing our opinion. The reasonable assurance is a high level assurance, but it is not a guarantee that the audit, conducted in compliance with IAS, always detects the material misstatements, if any. The misstatements may result from improper actions and errors and treated as material, if it's possible to reasonably suggest that they can influence, separately or in aggregate, the economic decisions of users, adopted on the basis of such annual accounting (financial) statements.

As part of audit conducted in compliance with IAS, we apply the professional judgment and reserve the professional skepticism during the whole audit. In addition, we:

a) reveal and assess risks of material misstatements of annual accounting (financial) statements due to improper actions or errors; develop and implement audit procedures in response to such risks; obtain audit evidences, being sufficient and proper, in order to serve as basis for our opinion. The risk of non-revealing of a material misstatement as a result of improper actions is higher than the risk of non-revealing of a material misstatement as a result of error, as improper actions may comprise concert, forgery, willful omission, misrepresentation of information or actions in circumvention of internal control system;

b) obtain understanding of internal control system, which is relevant for the audit, in order to develop the audit procedures, corresponding to the circumstances, but not for the purpose of expressing opinion on efficiency of internal control system of the audited entity;

c) assess proper nature of the applied accounting policy, validity of accounting judgments and

respective information disclosure, prepared by the management of the audited entity;

d) conclude on lawfulness of application by the management of the audited entity of assumption on continuity of business, and on the basis of obtained audit evidences – conclusion on whether there is a material uncertainty in connection with events or conditions, probably resulting in material doubts in ability of the audited entity to continue its business without interruptions. If we arrive at a conclusion on availability of material uncertainty, we should draw attention in our audit report to a respective information disclosure in the annual accounting (financial) statements or, if such information disclosure is not due, we should modify our opinion. Our conclusions are based on the audit evidences, obtained before the date of our audit report. However any future events or conditions may result in inability of the audited entity to continue its business;

e) assess the representation of the annual (financial) statements in general, its structure and contents, including disclosure of information, and whether the annual accounting (financial) statements represents the underlying operations and events as to ensure their reliable presentation.

We implement the information cooperation with the management of the audited entity, bringing to their attention, inter alia, information on the planned scope and timeframes of the audit, and on the material comments upon the results of audit, including on material defects of internal control system, which we reveal during the audit.

Audit firm:

Joint Stock Company "Audit Company "Best-Audit", OGRN 1027700591027, 117420, Moscow, Profsoyuznaya Street, 57, 7th floor, suite II, office 56 Member of Self-regulated Organization of Auditors "Russian Auditors Union" (Association) ORNZ (Principal Number of Registration Entry) 10303000020

General Director Audit Company "Best-Audit" JSC: /signature/ Egorov M.E.

(Qualification Certificate No. 03-000007, ORNZ (Principal Number of Registration Entry – 29403009516)

March 26, 2018

Seal: Joint Stock Company "Audit Company "Best-Audit" Moscow

Audit Opinion on Accounting (financial) Statements of Sun Pharmaceutical Industries LLC for 2017

Balance Sheet December 31 20 17 Codes as of 0710001 Form according to OKUD 12 2017 Date (day, month, year) 31 According to Limited Liability Company "Sun Pharmaceutical Industries" 83236036 Company OKPO 7728638440 Taxpayer identification number INN Acc. to Authorized business Wholesale trade in pharmaceuticals and medical goods OKVED 46.46.1 Incorporation form/ownership Acc. to 12300 Limited Liability Company/Joint private and foreign property OKOPF/OKFS 34 Unit of measurement: thousand rubles Acc. to OKEI 384

Location (address) 129223, Moscow, Mira prospekt, No. 119, bldg. 537/6, suite 62

Notes	Line item	Code	as of December <u>31, 2017</u>	as of December <u>31, 2016</u>	as of December <u>31, 2015</u>
	ASSETS		<u>31, 2017</u>	<u>31, 2010</u>	<u>51, 2015</u>
	ASSE15				
	I. NON-CURRENT ASSETS				
	Intangible assets	1110			
	R&D Results	1120	-	-	
	Intangible development assets	1130	-	-	
	Tangible development assets	1140	-	-	
1	Fixed assets	1150	50	251	49
	Income-bearing investments into tangible assets	1160	0	0	
	Financial investments	1170	0	0	
	Deferred tax assets	1180	10823	11361	1573
	Other non-current assets	1190	0	0	
	Total for Section I	1100	10873	11612	1622
	II. CURRENT ASSETS				
2.1	Inventories	1210	33	40	1186
	Including: Materials	12101	0	0	9
	Goods	12102	0	0	1163
	Prepaid expenses	12103	33	40	13
	Value Added Tax on purchased valuables	1220	-	-	
3.1	Accounts receivable	1230	1269	3382	13586
	Including:				
	Settlements with suppliers and contractors	12301	441	690	
	Settlements with buyers and customers	12302	0	0	12284
	Settlements for taxes and levies	12303	685	6	770
	Settlements for social insurance and security	12304	83	105	33
	Settlements with staff for salary	12305	-	-	
	Settlements with accountable persons	12306	-	-	
	Sottlements with staff for other transactions	12307	60	14	
	Settlements with staff for other transactions Settlements with various debtors and creditors	12308		2568	436
4			-	2568	430
4	Financial investments (except for cash equivalents)		- 1000		10591
	Cash and cash equivalents including:	1250	16928	21216	10581

Cash desk of the company	12501	-	-	-
Current accounts	12502	16900	21186	105784
Currency accounts	12503	28	29	35
Other current assets	1260	-	-	-
Total for section II	1200	18230	24637	253543
BALANCE	1600	29103	36250	269770

Form 0710001 p. 2

Notes	Line item	Code	as of December 31, 2017	as of December 31, 2016	as of December 31, 2015
	LIABILITIES				
	III. CAPITAL AND RESERVES				
	Authorized capital (joint capital, authorized fund, contributions made by partners)	1310	50	50	50
	Treasury shares redeemed from the shareholders	1320			
	Revaluation of non-current assets	1340	-	-	
	Additional capital (without revaluation)	1350	5 200	5 200	520
	Reserve capital	1360	5 200	5 200	520
	Undistributed profit (uncovered loss)	1370	(155246)	(153033)	(131004
	Total for section III	1300	(149996)	(/	(125754
		1200	(11)))0)	(11/105)	(125751
	IV. LONG-TERM LIABILITIES				
	Loans	1410	-	-	
	Including long-term loans Long-term loans (in foreign exchange)	14101			
	Deferred tax liabilities	14101	-	0	
	Estimated liabilities	1420	0	Ŷ	
	Other liabilities	1450	0	0	
	Total for section IV	1400	0	ů	
		1400	0	_	
	V. SHORT-TERM LIABILITIES				
	Loans including:	1510	98344	103511	12431
	Interests on long-term loans	15101		_	
	Interests on long-term loans (in foreign		-	-	
	exchange)	15102	424	394	41
	Short-term loans (in foreign exchange)	15103	97920	103117	12390
3.2	Accounts payable	1520	80339	80387	26963
	including:	15201	10	52	19026
	Settlements with suppliers and contractors Settlements with buyers and customers	15201 15202	16	53	18926
	Settlements with ouyers and customers Settlements for taxes and levies	15202	16	19	5
	Settlements for social insurance and security	15205	10	19	
	Settlements for social insurance and security	15204	-	8	
	Settlements with scale persons	15205	-	0	
	Settlements with staff for other transactions	15200	-	-	
	Settlements with starr for other transactions Settlements with various debtors and creditors	15207	80 307	80 307	80 31
	Deferred income	15200	80 307		
6	Estimated liabilities	1540	416	9	1580
U	Other liabilities	1550	410		1380
	Total for section V	1500	179099		39552
	BALANCE	1700	29103	36250	26977

Manager/signature/Syrkasheva Olga(signature)Vladimirovna(signature)(surname and initials)

"<u>26th</u>" of March 20<u>18</u>

<u>Round seal:</u> "Sun Pharmaceutical Industries" Limited Moscow

Profit and Loss StatementforJanuary-December20 17

	¥				
		071000	2		
	Date (da	y, month, year)	31	12	2017
Company Limited Liability Company "Sun Pharmaceutical Industries" acc. to OKPO					36
Taxpayer identification number INN					40
Authorized business	Wholesale trade in pharmaceuticals and medical goods	Acc. to OKVED		46.46.1	
Incorporation form/o	wnership				
Limited Liability Con	npany/Joint private and foreign propertyacc. to	OKOPF/OKFS	12300)	34
Units of measuremen	t: thousand rubles	acc. to OKEI		384	

Codes

			For	For
Notes	Line item	Code	January-December 2017	January-December 2016
	Proceeds	2110		123286
	Incuding:		-	
	Sales of prescription drugs			123286
5	Primary cost of sales	2120	-	(118492)
	including:		-	
	primary cost of prescription drugs			(118492)
	Gross profit (loss)	2100	-	4794
5	Commercial costs	2210	-	(3667)
	Including: depreciation of fixed assets	2211	-	(74)
	Rent of office and warehouse premises	2212	-	(805)
	Mandatory audit	2213	-	
	Salaries	2214	-	(1423)
	Insurance contributions	2215	-	(410)
	Transportation and customs clearance of the goods	2216	-	(798)
	Services for registration and expert evaluation of the drugs	2217	-	
	Other	2218	-	(157)
6	Management costs	2220	(5392)	(11581)
	Including: depreciation of fixed assets	2221	(201)	(287)
	Rent of office and warehouse premises	2222	(2570)	(3272)
	Mandatory audit	2223	(153)	(249)
	Salaries	2224	(1304)	(5043)
	Insurance contributions	2225	(379)	(1166
	Transportation and customs clearance of the goods	2226	-	(1165)
	Other	2227	(785)	(399)
	Sales profit (loss) Including:	2200	(5392)	(10454
	Sales of prescription drugs		-	(10454
	Profit of participation in other companies	2310	-	(20.01
	Interest receivable	2320	-	
	Interests payable	2330	(50)	(57
	including:	2000	(00)	(07)
	Interest accrued in compliance with Art 269 of Tax Code of the Russian Federation	23301	(50)	(57
	Other income:	2340	15126	59878
	Including: Profit connected with lease (sublease) of property	23401		12

Profits connected with sale of fixed assets	23402	-	127
Income in the form of restored valuation provisions	23403	2905	23468
Reimbursement of loss receivable	23404	-	86
Exchange rate differences	23405	12204	35999
Income in form of written-off accounts payable	23406	17	74
Other income	23407	-	112
Other expenses	2350	(10865)	(67020)
Including: Expenses connected with sale of fixed assets	23501	-	(94)
Expenses in form of created valuation provisions	23502	(3074)	(14830)
Banks fee	23503	(72)	(351)
Fines, penalties and forfeitures payable	23504	-	(11565)
Exchange rate differences	23505	(6988)	(15149)
Taxes and levies	23506	(7)	(55)
Expenses in form of written-off accounts receivable	23507	(92)	(3216)
Other loss referred to the non-sale expenses	23508	(632)	(2659)
Destruction of drugs	23510	-	(18934)
Financial bonus according to the terms of agreement	23511	-	(167)
Profit (loss) before taxation	2300	(1181)	(17653)
Current profit tax	2410	(516)	-
Including permanent tax liabilities (assets)	2421	(1268)	(7907)
including:			
permanent tax liabilities (assets)		(1268)	(7907)
Changes in deferred tax liabilities	2430	-	-
Change in deferred tax assets	2450	(516)	(4376)
including:			
deferred tax assets		(516)	(4376)
Other	2460	-	-
Net profit (loss)	2400	(2213)	(22029)

Form 0710002 p.2

Notes	Line item		For	For
		Code	January-December	January-December
			2017	2016
	FOR REFERENCE ONLY			
	Result of revaluation of non-current assets, not included into net profit (loss) of the period	2510	-	-
	Result of other transactions, not included into net profit (loss) of the period	2520	-	-
	Aggregate financial result of the period	2500	(2213)	(22029)
	Basic profit (loss) per share	2900	-	-
	Diluted profit (loss) per share	2910	-	-

 Manager
 /signature/ (signature)
 Syrkasheva Olga Vladimirovna

 (signature)
 (surname and initials)

"<u>26th</u>" of March 20<u>18</u>

Round seal: "Sun Pharmaceutical Industries" Limited Moscow

Statement of change	es in equity			
for <u>January-Decem</u>	<u>ıber</u> 20 <u>17</u>		Co	odes
	Form acco	rding to OKUD	071	0003
	Date (da	y, month, year)	31	2017
Company Limited Liability Company "Sun Ph	narmaceutical Industries"	acc. to OKPO	8323	36036
Taxpayer identification number		INN	77286	538440
Authorized business Wholesale trade in pharma	ceuticals and medical goods	Acc. to OKVED	46.	46.1
Incorporation form/ownership				
Limited Liability Company/Joint private property	acc. to	OKOPF/OKFS	12300	34
Units of measurement: thousand rubles		acc. to OKEI	3	84

1. Capital flow

Line item	Code	Authorized capital	Treasury shares redeemed from the shareholders	Additional capital	Reserve capital	Undistributed profit (uncovered loss)	Total
Capital amount as of December 31, 2015	3100	50	-	5200	a.	(131004)	(125754)
<u>For 2016</u>							
Capital increase - total:	3210	-	-	-		-	a
including: net profit	3211	Х	Х	Х	Х	-	-
property revaluation	3212	Х	Х		Х	-	-
profit referred directly to the capital increase							
	3213	Х	Х	-	Х		-
additional share issue	3214	-	-	-	Х	Х	-
increase in nominal value of shares	3215	-	-		Х	-	Х
corporate entity restructuring	3216	-	-	-	-	-	-

Line item	Code	Authorized capital	Treasury shares redeemed from the shareholders	Additional capital	Reserve capital	(uncovered loss)	Total
Capital decrease - total:	3220	-	-	-	-	(22029)	(22029)
including: loss	3221	X	Х	Х	Х	(22029)	(22029)
property revaluation	3222	Х	X	-	Х	-	-
costs referred directly to the capital							
decrease	3223	X	Х	-	Х	-	-
decrease of nominal values of shares	3224	-	-	-	Х	-	-
decrease in number of shares	3225	-	-	-	Х	-	-
corporate entity restructuring	3226	-	-	-	-	-	-
dividends	3227	Х	Х	Х	Х	-	-
Change of additional capital	3230	Х	Х	-	-	-	Х
Change of reserve capital	3240	Х	Х	Х	-	-	Х
Capital amount as of December 31, 20 <u>16</u>	3200	50	-	5200	-	(153033)	(147783)
For 2017							
Capital increase - total:	3310	-	-	-	-	-	-
including: net profit	3311	Х	Х	Х	Х	-	-
property revaluation	3312	Х	Х	-	Х	-	-
profit referred directly to the capital							
increase	3313	Х	Х	-	Х	-	-
additional share issue	3314	-	-	-	Х	Х	-
increase in nominal value of shares	3315	-	-	-	Х	-	Х
corporate entity restructuring	3316	-	-	-	-	-	-
Capital decrease - total:	3320	-	-	-	-	(2213)	(2213)
including: loss	3321	Х	Х	Х	Х	(2213)	(2213)
property revaluation	3322	Х	Х	-	Х	-	-
costs referred directly to the capital							
decrease	3323	Х	Х	-	Х	-	-
decrease of nominal values of shares	3324	-	-	-	Х	-	-
decrease in number of shares	3325	-	-	-	Х	-	-
corporate entity restructuring	3326	-	-	-	-	-	-
dividends	3327	Х	Х	Х	Х	-	-
Change of additional capital	3330	Х	Х	-	-	-	Х
Change of reserve capital	3340	Х	Х	Х	-	-	Х
Capital amount as of December 31, 20 <u>17</u>	3300	50	-	5 200	-	(155246)	(149996)

	2. Cor	rections due to chan	ges in accounting pol	icy and correction of	errors
Line item	Code	As of December 31, 20 <u>17</u>	Changes in ca	apital for 20 <u>16</u> for the account of other factors	As of December
Total capital					
before corrections	3400	-	-	-	-
correction due to:					
changes in accounting policy	3410	-	-	-	-
correction of errors	3420	-	-	-	-
after corrections	3500	-	-	-	-
including:					
Unbdistributed profit (uncovered loss):					
before corrections	3401	-	-	-	-
correction due to:					
changes in accounting policy	3411	-	-	-	-
correction of errors	3421	-	-	-	-
after corrections	3501	-	-	-	-
before corrections	3402	-	-	-	-
correction due to:	5102				
changes in accounting policy	3412	-	-	-	-
correction of errors	3422	-	-	-	-
after corrections	3502	-	-	-	-

Line item	Code	As of December 31 20 <u>17</u>	As of December 31 20 <u>16</u>	As of December 31 20 <u>15</u>
Net Assets	3600	(149996)	(147 783)	(125 754)

3. Net assets

		Syrkasheva Olga
Manager	/signature/	Vladimirovna
	(signature)	(surname and initials)

"<u>26th</u>" of March 20<u>18</u>

Round seal: Sun Pharmaceutical Industries Limited Moscow

Cash flow Statement as of January-December 20 17

	Fo	orm according to O	KUD		071000	4
		Date (day, month,	year)	31	12	2
Company Limited Liability Company "Sun Pharmaceutical Industries" acc. to OKPO 8						6
Taxpayer identificati	on number		INN	7′	7286384	40
Authorized business	Wholesale trade in pharmaceuticals and medical		CC. to		46.46.1	
Incorporation form/o	wnership					
Limited Liability Co	mpany/Joint private property and foreign property	acc. to OKOPF/O	OKFS	12300)	34
Units of measuremer	t: thousand rubles	acc. to (OKEI		384	

Codes

2017

34

4110 4111	2 603	
	2 603	
4111		236 911
4111		
	-	234 903
4112	-	15
4113	-	-
4114	2 603	1 993
4119	-	-
4120	(6 890)	(321 452)
		, , , , , , , , , , , , , , , , , , ,
4121	(3 283)	(310 717)
4122	(1 673)	(8 127)
4123	-	0
4124	(1 208)	0
	-	0
-	(726)	(2 608)
-	()	(84 541)
1100	(1207)	(01511)
4210	-	127
4211	_	127
	_	_
1212		
4213	_	_
4214	_	_
	_	_
	_	_
	_	(183)
4220		(105)
4221		(183)
7221		(105)
4222	_	_
-		-
		<u> </u>
-		(56)
	4113 4114 4119 4120 4121 4122	$\begin{array}{cccccccccccccccccccccccccccccccccccc$

Form 0710004 p. 2

		For January-December	For January-December
Line item	Code	2017	2016
Cash flow of financial transactions			20 <u>10</u>
Total proceeds	4310	_	-
including:			
Getting loans and credits	4311	-	-
Monetary contributions of owners (members)	4312	-	-
Issue of shares, increase of participatory interests	4313	-	-
Issue of debentures, bills of exchange and other debt securities			
etc.	4314	-	-
	4315	-	-
Other proceeds	4319	-	-
Total payments	4320	-	-
including:			
To owners (members) due to redemption of their shares			
(participatory interests)	4321	-	-
Payment of dividends and other distributions to owners	4322	-	-
repayment (redemption) of bill of exchange and other debt			
securities	4323	-	-
	4324	-	-
Other payments	4329	-	-
Balance of cash flow of financial transactions	4300	-	-
Balance of cash flow for the reported period	4400	(4287)	(84 597)
Balance of cash and cash equivalents as of the beginning of the	e		
reported period	4450	21 216	105 819
Balance of cash and cash equivalents as of the end of the			
reported period	4500	16 928	21 216
Effect of foreign exchange/Russian rate changes	4490	(1)	(6)

Manager/signature/
(signature)Syrkasheva Olga
Vladimirovna(signature)(surname and initials)

"<u>26th</u>" of March 20<u>18</u>

Round seal: "Sun Pharmaceutical Industries" Limited Moscow

SUN PHARMACEUTICAL INDUSTRIES

Moscow, 129223, Prospekt Mira Str., 119, bldg. 537/6, suite 62 Telephone: (495) 234-56-11

NOTES to the Balance Sheet and Profit and Loss Statement of Sun Pharmaceutical Industries LLC for 2017

1. General Provisions.

Information on incorporation form, name and officers

Full name of the company: Limited Liability Company Sun Pharmaceutical Industries

Short name: Sun Pharmaceutical Industries LLC

Name in foreign language (English): Sun Pharmaceutical Industries Limited

INN 7728638440 KPP 771701001

Director: Kanniputur Kuppuswami Kamalakkannan, citizen of the Republic of India

Chief Accountant – Syrkasheva Olga Vladimirovna, was elected Director on 16.01.2018 in virtue of Resolution of the Founding Member No. 17 dated 16.01.2018.

Information on address (location)

Location of the Company: 129223, Moscow, prospekt Mira Str., 119, building 537/6

Address of permanent executive body:

129223, Moscow, prospekt Mira Str., 119, building 537/6, suite 62

Contact telephone/fax: (495) 234-56-11

Information on capital

Amount of the authorized capital – 50,000.00 rubles (paid by 100%).

Information on incorporation of the legal entity and registration authority

Date of registration - 12.11.2007

Main State Registration Number (OGRN) 1077762356770

Registration authority: Interdistrict Inspectorate of the Federal Tax Service of Russia No. 46 in the city of Moscow

Information on record with tax authority

Tax authority: Inspectorate of Federal tax Service No. 28 in the city of Moscow (code 7728) Date of registration: 12.11.2007

Certificate of registration: series 77 No. 008605715 valid till 28.07.2015,

Tax authority: Inspectorate of Federal tax Service No. 17 in the city of Moscow (code 7717)

Date of registration: 29.07.2015

Certificate of registration: series 77 No. 017228646 since 29.07.2015,

<u>Information on founding members</u> Number of founding members – 1. Founding member – foreign legal entity: Sun Pharmaceutical Industries Limited, manufacturer of pharmaceuticals

Country of incorporation: Republic of India

Address: SPARK, Tandalia, Baroda-390 020, Gujarat, INDIA

Date of registration: 01.03.1993

Registration number: 04-19050

Registration authority: Department of Registration of Business Companies of Gujarat

Amount of contribution to the authorized capital by the founding member: 50 000 rubles.

Information on businesses and licenses

Main business – wholesale trade in pharmaceuticals and medical goods (OKVED code - 46.46.1)

License for pharmaceutical business No. FS-99-02-005430 dated 15.06.2016, issued by Federal Service for supervision in the field of healthcare, without limitation in time, to exercise at the address: 129223, Moscow, Prospekt Mira Str., 119, bldg. 537/6 and at the address: 143581, Moscow region, Istrinsky district, village Leshkovo, 248, bldg. 4.

Number of employees as at the reported date - 2 persons

Information on detached divisions

The detached division – warehouse of pharmaceuticals is located at the address: 143581, Moscow region, Istrinsky district, village Leshkovo, bldg.248, 2-4. (KIIII 501745001)

The detached division does not have a status of a legal entity, it does not own detached property, separate balance, and current accounts opened in the banks.

2. Information on business

The company does not refer to a small business entity, it applies a standard taxation scheme and practices PBU 18/02 "Profit tax accounting". In compliance with the Articles of Association of the Company, its main business is a wholesale trade in pharmaceuticals and medical goods. The Company did not trade during 2017.

The Company did not carried out investment business during the reported year.

3. Main elements of accounting policy of the Company.

Accounting statements for 2017 were prepared in compliance with the requirements of Russian laws with respect to preparation and presentation of the accounting statements, and Accounting policy of the Company, approved by Order dated 30.12.2016 No. 18, which is prepared according to requirements of Federal Law dated 06.12.2011 No. 402-FZ "On accounting", Accounting regulation "Accounting Policy of Companies" PBU 1/2008, approved by the Order of the Ministry of Finance of the Russian Federation dated 06.10.2008 No. 106n, Accounting regulation "Accounting records of companies" PBU 4/99, approved by the Order of the Ministry of Finance of the Russian Federation dated 06.07.1999 No. 43n, Order of the Ministry of Finance of the Russian Federation dated 02.07.2010 No. 66n "On forms of accounting", and in compliance with PBU 8/2010 "Estimated liabilities, contingent liabilities and contingent assets", approved by the Order of the Ministry of Finance of the Russian Federation dated 13.12.2010 No. 167n and any other regulations and accounting methodological documents.

Organizational and technical aspects of accounting policy

- Accounting and tax accounting are carried out by accounting department under the management of Chief Accountant;

- The accounting is carried out with the help of special accounting software 1C: Enterprise UPP 8.2.

- As working chart of accounts, the Company uses the chart of accounts from 1C software, which is created on the basis of model Chart of accounts approved by the Order of the Ministry of Finance of the Russian Federation dated 31.10.2000 No. 94n

- The Company uses the ledgers for accounts and tax records generated by 1C software.

Main elements of accounting policy for the purposes of accounting:

- Accounting of property, liabilities and business transactions is carried out in Russian rubles and kopecks;

- The figure of 10 per cent is a materiality guideline;

- The unified forms approved by the State Statistics Committee of Russia are used as the forms of primary accounting documents. In addition, the Company uses the forms generated by 1C software;

- The forms indicated in appendix to the Order of the Ministry of Finance of Russia dated 02.07.2010 No. 66n are used as accounting records forms;

- Document flow Schedule is subject to approval by a separate order of Director;

- Inventory taking of assets and liabilities is carried out in compliance with the procedure approved by the Order of the Ministry of Finance of Russia dated 13.06.95 No. 49. The terms of inventory taking for the selected types of assets and liabilities are subject to separate orders of Director;

- Limit cost of assets recognized within the fixed assets is 100 000 rubles;

- A single method of depreciation accrual, i.e. linear method, is used for all fixed assets;

- Useful life of fixed assets is determined proceeding from the Classification of fixed assets, included into depreciation groups, approved by the Order of the Government of the Russian Federation dated 01.01.02 No. 1;

- Provision for repair of fixed assets is not formed;

- Expenses for the repair are recorded in the accounts of the reported period, during which such repairs were done;

- A single method of depreciation accrual, i.e. linear method, is used for all intangible assets;

- Stock number is a unit of account of materials;

- The materials are recognized by actual prices;

- For a;; materials valuation, when they are transferred for sale or other purposes, the Company uses a single method, i.e. average primary cost method;

- Transport and procurement expenses during the purchase of goods are included into the primary cost of the purchased goods;

- The primary cost of the purchased goods is formed in account 15 "Procurement and purchase of tangible assets" without using account 16 "Deviation in cost of tangible assets";

- In order to evaluate all goods, when they are transferred to sale or other purposes, the Company uses a single method – cost of goods is transferred to expenses at their average primary value;

- Special tooling and overalls are recognized in manner prescribed for the accounting of materials and supplies inventories;

- Expenses for obtaining of loans are recognized for a total amount in the same reported period, when such expenses were incurred;

- The Company creates the Provisions for doubtful debts, for decrease in value of inventories, incurred costs without documentary support, bonuses for customers;

- Permanent and temporary differences are recorded in the accounts on the basis of primary accounting documents and affect tax accounts immediately, which names and intended purposes are similar;

The amounts of deferred tax asset and deferred tax liability are recorded separately in accounts.

Main principles of accounting policy for the purposes of taxation:

Accounting policy with respect to profit tax

- The facilities complying with the requirements of Articles 256 and 257 of Tax Code of the Russian Federation, which useful life is more than 12 months and primary cost is more than 100 thousand rubles, are recognized within the depreciated assets;

- Increasing and decreasing factors of depreciation value are not used;
- When selling the bought-in goods, their acquisition cost is determined according to average cost;

- Provisions (for repairs of fixed assets, for doubtful debts, for warranty repairs and maintenance) are not formed;

- Three, six and nine months of the calendar year are regarded as reported periods for the purposes of profit tax;

- Settlements for profit tax are made by payment of monthly advance payments;

- Profit and loss are recognized by accrual method;

- The acquisition cost of goods for sale comprises the purchase price of the goods, customs fees and levies, costs for delivery of the goods to the company's warehouse, other costs related to acquisition of the goods;

- The cost of the acquired goods is recorded with account 15 and without using account 16;

- The taxes accrued to the detached division are paid by the head company at place of its location;

- Taxable profit falling to the detached division located in other place than the head company, is determined pro rata to the average number of staff;

Accounting policy for value added tax

- The transactions imposed at the rates of 10 and 18 per cent, and exempt transaction are recorded separately in accounting and tax accounting ledgers;

- For goods (works, services, proprietary interests), used both in transactions subject to VAT and exempt transactions, the deduction amount is determined pro rata to the value of goods (works, services, proprietary interests), shipped during the reported quarter and subject to VAT, within the total value of goods (works, services, proprietary interests), shipped during the reported quarter;

- The detached divisions do not issue pro forma invoices and do not keep purchase ledgers and sales ledgers;

- Tax accounting data are collected in tax accounting ledgers on the basis of the primary documents, including the accounting notes.

4. Main exponents of Company's business and information on financial standing.

The Company didn't carry out business of wholesale trade in drugs in 2017.

The Company incurred costs associated with management expenses amounted to 5 392 thousand rubles, which was classified as operational costs.

In 2017 the other accounting income amounted to 15 126 thousand rubles, other expenses amounted to 10 865 thousand rubles. The income of non-sale transactions amounted to 4 261 thousand rubles.

Within other revenues and expenses, the main part falls to exchange rate differences and income of exchange rate differences amounted to 12 204 thousand rubles, loss of exchange rate differences amounted to 6 988 thousand rubles;

Profit of the exchange rate differences amounted to 5 216 thousand rubles.

Upon the results of the reported year, the loss before taxation for accounting amounted to 1 181 thousand rubles.

The profit in tax accounting amounted to 5 160 thousand rubles due to non - recognition of management costs, which 50% reduced the balance of the loss not carried forward by the end of the year. The current income tax in the amount of 516 thousand rubles was imposed on the rest of amount of 2 580 thousand rubles.

Clearing off of deferred tax assets -516 thousand rubles. Provisional profit tax loss -236 thousand rubles Permanent tax asset -581 thousand rubles. Permanent tax liability -1849 thousand rubles. Change in deferred tax liabilities -1268 thousand rubles.

Net loss in accounting amounted to 2 213 thousand rubles.

The proceeds and payments are recorded in section "Cash flow of current transactions" of Cash Flow Statement with consideration of the comparability for 2016 and 2017, net of VAT.

VAT amount is indicated in a compressed form in line 4129 "Other revenue":

- for 2016 - 2 335 thousand rubles

VAT amount is indicated in a compressed form in line 4129 "Other payments":

- for 2017 - 590 thousand rubles.

Comparison of main balance sheet ratios of the Company with the same period of the last year:

In 2016 the Company received sales proceeds amounted to 123 286 thousand rubles, primary cost of sales was 118 492 thousand rubles, total amount of loss incurred of the main business was 3 667 thousand rubles, management expenses were 11 581 thousand rubles. The loss of sales was 10 454 thousand rubles. The sales proceeds by 100% occurred in the reported period.

In 2016 other income in accounting amounted to 59 878 thousand rubles, other expenses were - 67 020 thousand rubles. Loss of non-sale transactions amounted to 7 142 thousand rubles. The loss decreased by 100% as compared with the previous year.

According to results of 2016 results, the Company incurred a loss in accounts in the amount of 17 653 thousand rubles and decrease of loss before taxation by 93,31% in the reported year.

In 2016 the Company encountered the profit of 21 844 thousand rubles recorded in tax accounting? Which reduced the balance of previous years' loss not carried forward by the end of the year. The decrease of net loss amounted to 89,95% in the reported year.

Information on transactions in foreign exchange

In 2017 the Company carried out transactions in foreign exchange (USD): accrual of interest on loan, revaluation of assets and liabilities in foreign exchange as at the transaction date and accounts preparation date.

The exchange rate differences in 2017 were caused by revaluation of assets and liabilities in foreign exchange (loan liabilities, cash on currency accounts). The profit of 5 216 thousand rubles was incurred due to exchange rate differences upon the results of 2017.

Exchange rate of the Central Bank of the Russian Federation applied as at the reported date of accounting statements (as at 31.12.2017):

1 USD = 57,6002 rubles

Settlements for profit tax (application of rules of PBU 18/02).

The substantial discrepancies between the accounting and tax records are caused by the fact that the following expenses were not accepted for the purposes of taxation in the reported year (permanent differences occurred):

- amounts of management expenses – 5 392 thousand rubles

- amounts of written-off VAT (amounts of VAT not accepted for refund from the budget) - 581 thousand rubles

- amounts of provision for inventory depreciation (this provision is not created within tax accounting) - 170 thousand rubles

Provisions and estimated liabilities

In 2017, the previous provision for doubtful debts was cleared in accounting in the amount of 4 375 thousand rubles (the buyers repaid the doubtful debt for supplied goods). As at 31.12.2017, the provision for doubtful debts was created in the amount of 288 thousand rubles, provision for vacations -139 thousand rubles, provision for annual bonus -79 thousand rubles, provision for current expenses -198 thousand rubles were formed.

No provisions were created within the tax accounting.

Loan liabilities and maturity periods

The line 15103 of the Balance Sheet records the loan liabilities in rubles -97920 thousand rubles (in foreign exchange in the amount of USD 1 700 000). Maturity of loans falls to April 2018.

5. Explanation of information set out in the accounting statements.

			As of be	g. of year			Changes	for period			As of the end of year	
						Retire	d items		Revaluation			
Line item	Code	Period	Primary cost	Accumulated depreciation	Receipt	Primary cost	Accumulate		Primary cost Accumulated depreciation			Accumulate d
				depreciation	I I		depreciation	Accrued depreciation		depreclation		depreciation
Total Fixed assets (without	5200	for 2017	1155	(904)	-	(426)	426	(201)	-	-	729	(679)
consideration of income-bearing investments into tangible assets)												
	5210	for 2016	2152	(1662)	216	(1213)	1118	(360)	-	-	1155	(904)
Including: Vehicles	5201	for 2017	_	-	-	-	_	-	-	-	_	_
	5211	for 2016	1213	(977)	-	(1213)	1118	(141)	-	-	-	-
Machines and equipment (except	5202	for 2017	1098	(847)	-	(369)	369	(201)	-	-	-	-
for office machines and equipment)	5212	for 2016	882	(628)	216	-	-	(219)	-	-	1098	(847)
Office equipment	5203	for 2017	57	(57)	-	(57)	57	-	-	-	-	-
	5213	for 2016	57	(57)	-	-	-	-	-	-	57	(57)
Other fixed assets	5204	for 2017										
	5214	for 2016	-	-	-	(204)	204	-	-	-	-	-
Total; recognized within	5220	for 2017	-	-	-	-	-	-	-	-	-	-
income-bearing investments into												
material valuables	5230	for 2016	-	-	-	-	-	-	-	-	-	-
Including:												
	5221	for 2017	_					-	-	-	-	
	5231	for 2016	-	-	-	-	-	-	-		-	-

1. Fixed Assets 1.1. Fixed assets availability and flow

<u>1.2. Capital investments in progress</u>

					Changes for period	-	
Line description	Code	Period	As of beginning of year	Costs during the period	retired	Accepted for recognition of fixed assets of cost is increased	As of the end of the period
Total construction in progress and transactions in	5240	for 2017	-	-	-	-	-
progress for acquisition, upgrading etc. of fixed assets				216		(216)	
	5250	for 2016	a.				
Including:							

Monoblock MGM107S, compress-kondens aggregate	5241	for 2017	-				-
LH64/2DC-3.2Y+NHB 078E	5251	for 2016	a	216	-	(216)	-
	5242	for 2017		-	-	-	*
	5252	for 2016	*		-	-	
	5243	for 2017			-	-	-
	5253	for 2016	-	-	-	-	-
	5244	for 2017	-	-	-	-	-
	5254	for 2016			-	-	
	5245	for 2017				-	
	5255	for 2016	-	-	-	-	-

1.3. Change in cost of fixed assets as a result of further construction, further equipping,

reconstruction and partial liquidation

Line description	Code	for 2017	for 2016
Total increase in costs of fixed assets as a result of further			
construction, further equipping, reconstruction	5260		216
Including: Refrigeration camera and equipment, compressor base Bitzer(Germany)	5261		216
Total decrease of cost of fixed assets as a result of partial			
liquidation:	5270	-	-
including:			
	5271	-	-

1.4. Other use of fixed assets

Line item	Code	As of December 31, 2017	As of December 31,2016	5
Fixed assets transferred into rent, accounted in balance	5280	-	-	-
Fixed assets transferred into rent, accounted out of balance	5281	-	-	704
Fixed assets received into rent, accounted in balance	5282	-	-	-
Fixed assets received into rent, accounted out of balance	5283	324	324	-
Real estate facilities accepted for operation and actually used, in the course of state registration	5284	-	-	-
Laid up fixed assets	5285	-	-	-
Other use of fixed assets (pledge etc.)	5286	-	-	-

2. Inventories 2.1. Availability and flow of inventories	
2.1. Availability and flow of inventories	

				g. of year			Cha	nges for per	riod		As of the end of year	
							Reti	red	Loss of	Turnover of		
Line item	Code	Period	Primary cost	Inventory provision	Receipts costs	and	Primary cost	Inventory provision	decrease in cost	inventory between their groups (types)	Primary cost	Inventory provision
Total inventory	5400	for 2017	40	-	108		(115)	-	-	Х	33	
i otar mventory	5420	for 2016	19 231	(7 369)	122 461		(141 652)	18 859	(11 490)	8014	40	-
including: Raw stuff, materials and other	5401	for 2017	_	-	_		-	-	-	-	-	-
similar inventories	5421	for 2016	90	_	25		(115)	-	-	-	-	-
Finished products	5402	for 2017	-	-	-		-	-	-	-	-	-
	5422	for 2016	-	-	-		-	-	-	-	-	-
Goods for resale	5403 5423	for 2017 for 2016	- 19 003	- (7 369)	- 118 423		- (137 426)	- 18 859	- (11 490)	- 8 014	-	-
Shipped goods and finished	5404	for 2017	19 003	(7 309)	110 423		(137 420)	10 039	(11 490)	0 014	-	
products	5424	for 2016	-		-			-	_	_	-	-
Expenses in production in	5405	for 2017	-	_	-		_	-	-	_	_	-
progress	5425	for 2016	-	-	-		-	-	-	-	-	-
Other inventories and costs	5406	for 2017	-	_	-		_	-	_	_	-	-
	5426	for 2016	-	-	3 667		(3 667)	-	-	-	-	-
Prepaid expenses (for analytic	5407	for 2017	40	-	108		(115)					
accounts, which are set out in balance within "Inventories")	5427	for 2016	138	-	346		(444)	-	-	-	40	-

3. Accounts receivable and Accounts payable 3.1 Availability and flow of accounts receivable

											As at the e	nd of period
			As of begin	ning of period			Changes	for period				
					Rece	eipt		Retired				
Line item	Line item Code	Code Period	Recognized under the terms of agreement	Amount of provision for doubtful debt	As a result of business transactions (debt amount under the transaction)	Outstanding interest, fines and other accruals	Repayment	Writing-off to finance result	Provision recovery	Transfer from long-term to short-term debt	Recognized under the terms of agreement	Amount of reserve for bad debt
	5501	for 2017	-	-	-	-	_	-	-	-	-	-
Total long-term accounts receivable	5521	for 2016	-	-	-	-	-	-	_	-		•
	5502	for 2017	-	-	-	-	-	-	-	-	-	-
Including: Settlements												
with buyers and customers	5522	for 2016	_	_	-	-	_	-	_	-	_	-
Issued advances	5503	for 2017	-	-	-	-	-	-	-	-	-	-
	5523	for 2016	-	-	-	-	_	-	-	-	-	-
Other	5504	for 2017	-	-	-	-	_	-	-	-	-	-
	5524	for 2016	-	-	-	-	_	-	-	-	_	-
	5505	for 2017	-	-	-	-	_	-	-	-	-	-
	5525	for 2016	-	-	-	-	_	-	_	-	-	-
	5510	for 2017	8044	(4662)	231	-	(7416)	-	4374	698	1557	(288)
Total short-term accounts										-		
receivable	5530	for 2016			548	60	(132 950)	-	(138)		8 044	(4662)
	5511	for 2017	4518	(4518)	-	-	(4299)	-	4299	-	219	(219)
Including: Settlements												
with buyers and customers	5531	for 2016		(4524)	-	-	(122 855)	-	6		4 518	(4 518)
Issued advances	5512	for 2017			201	-	(450)	-	-		441	-
	5532	for 2016			548	-	(473)	-	-		690	-
Other	5513	for 2017		(144)	30	-	(2667)	-	75	698	897	(69)
	5533	for 2016	12 398	-	-	60	(9 622)	-	(144)	-	2 836	(144)
	5514	for 2017	-	-	-	-	-	-	-	-	-	-
	5534	for 2016	-	-	-	-	-	-	-	-	-	-
Total	5500	for 2017	8044		231	-	(7416)	-	4374	Х	1557	(288)
ſ	5520	for 2016	140 386	(4 524)	548	60	(132 950)	-	(138)	Х	8 044	(4 662)

3.2. Availability and flow of accounts payable

					Changes f	or period		
				Receipt		Retired		
Line item	Code	Period	Balance as at the beginning of period	As a result of business transactions (debt amount under the transaction)	Outstanding interest, fines and other accruals	Repayment	Transfer from long-term to short-term debt	Balance as at the end of period
Total long-term Accounts payable	5551	for 2017	_	-	_	-	-	-
	5571	for 2016	-	-	-	-	-	-
including: credits	5552	for 2017	_	_	_	-	-	_
	5572	for 2016	-	-	-	-	-	-
loans	5553	for 2017	-	-	-	-	-	-
	5573	for 2016	-	-	-	-	-	-
other	5554	for 2017	-	-	-	-	-	-
	5574	for 2016	-	-	-	-	-	-
Total short-term Accounts payable	5560	for 2017	183 898	(10)	40	(5 943)	698	178 683
	5580	for 2016	393 944	-	3	(210 049)	-	183 898
including: settlements with suppliers and	5561	for 2017	53	-	-	(37)	-	16
contractors	5581	for 2016	189 265	-	-	(189 212)	-	53
Received advances	5562	for 2017						
	5582	for 2016	-	-	-	-	-	-
Settlements for taxes and levies	5563	for 2017	19	(10)	10	(701)	698	16
	5583	for 2016	56	-		(37)	-	19
Credits	5564	for 2017	103 117			(5197)		97 920
	5584	for 2016	123 900	-	-	(20 783)		103 117
Interest on loan Other	5565	for 2017	394		30			424
	5585	for 2016	411		-	(17)	-	394
	5566	for 2017	80 315	-	-	(8)	-	80 307
	5586	for 2016	80 312		3		-	80 315
	5567	for 2017	-	-	-	-	-	-
	5587	for 2016	-	-	-	-	-	-
Total	5550	for 2017	183 898	(10)	40	(5 943)	698	178 683
	5570	for 2016	393 944	-	3	(210 049)	Х	183 898

4. Financial investments 4.1. Availability and flow of financial investments

			As of beginning of the year		Change for the period					As of the end of the period	
						retired (c	leared)				
Line item	Code	Period	Primary cost	Accumulated correction	Receipt	Primary cost	Accumulate d correction	Accrual of interest (including bringing of primary cost to nominal cost)	Current	Primary cost	Accumulate d correction
Long-term investments -	5301	for 2017	-	-	-	-	-	-	-	-	-
total	5311	for 2016	-	-	-	-	-	-	-	-	-
including:	5302	for 2017	-	-		-	-	m		-	-
	5312	for 2016	-	-	-	-	-	-	-	-	-
Short-term investments -	5305	for 2017	-	-	-	-	-	-	-	-	-
total	5315	for 2016	-	-	-	-	-	-	-	-	-
	5306	for 2017		-	-	-	-	-	-	-	-
Including:	5316	for 2016	-	-	-	-	-	-	-	-	-
Financial investments -	5300	for 2017	-	-	-	-	-	-	-	-	-
TOTAL	5310	for 2016	-	-	-	-	-	-	-	-	-

5. Production costs

Line item	Code	for 2017	for 2016
Tangible costs	5610	-	118 492
Salaries	5620	1 304	6 466
Social security withholdings	5630	379	1 576
Depreciation	5640	201	361
Other costs	5650	3508	6 845
Total by items	5660	5 392	133 740
Change (increase [-]): in production in progress, finished products etc.	5670	-	-
Change (decrease [+]): in production in progress, finished products etc.	5680	-	-
Total costs for ordinary business	5600	5 392	133 740

6. **Estimated liabilities**

Line item	Code	Balance as of beginning of year	Recognized	Retired	Written-off as excessive amount	Balance as of the end of period
Total estimated liabilities	5700	135	3373	(188)	(2904)	416
including: Estimated liabilities for payment of paid leave	5701	65	183	(109)	-	139
Estimated liabilities for payment of annual bonus	5702	42	116	(79)	-	79
Estimated liabilities for payment of bonus to buyers	5703	-	459	-	(459)	-
Estimated liabilities for actual costs	570	28	2615	-	(2445)	198

7. Security of liabilities						
Line description	Code	As of December 31, 2017	As of December 31, 2016	As of December 31, 2015		
Total received	5800	-	-	-		
including:						
	5801	-	-	-		
Total issued	5810	-	-	13		
including:						
Security for contracts under the electronic auctions	5811	-	-	13		

6. Information on related parties.

The Company did not have any transactions with such related party in 2017.

7. Events after reporting date.

In accordance with the point 3 PBU 7/98 «Events after reporting date» the event after the reporting date is understood as the fact of economic activity which exerted or can exert the impact on the financial condition, cash flow or results of the company's business and which takes place between the reported date and signature date of accounting records for the financial year.

The company has no such relevant facts of economic activity to be recognized as events after reporting date in the financial statements for 2017.

8. Contingencies of business.

The Company did not have any contingencies of business during economic activity in 2017.

9. Results and prospects

The Company did not carry out trade business, i.e. wholesale trade in pharmaceuticals manufactured by the Indian company Sun Pharmaceuticals Industries Limited (India).

Loss of non-sale transactions amounted to 4 261 thousand rubles.

Loss before taxation in accounting records amounted to -1 181 thousand rubles

At the reported year-end, the Company incurred a net loss of 2 213 thousand rubles

In 2017 the Company did not extend the markets of sales of the drugs, decreased considerably the number of the buyers and sales volume in comparison with 2016.

However negative net assets still remain in the Company. They amounted in 2015 - (125754) thousand rubles, in 2016 - (147783) thousand rubles and in 2017 - (149966) thousand rubles at the background of the invariable amount of the authorized capital of 50 thousand rubles.

The main reason is still a loss incurred during financial and business transactions mostly due to other expenses and management costs and absence of trade business during 2017.

Furthermore the Company does not have any intentions to terminate or further reduce substantially its business. Responsible persons of the company management explore various options of business expansion, development of new trends and market research.

		Syrkasheva Olga
Manager	/signature/	Vladimirovna
	(signature)	(surname and initials)

"<u>26th</u>" of March 20<u>18</u>

<u>Round seal:</u> Sun Pharmaceutical Industries Limited Moscow Total of 30 pages are numbered, stitched and sealed

General Director

Best-Audit JSC /signed/ M.E. Egorov

Seal: Closed Joint Stock Company Best – Audit Moscow

Перевод с русского языка на английский язык выполнил переводчик Ковалев Игорь Николаевич